NCT05083247 - Preoperative mFOLFIRINOX (or Gem-Nab-P) +/- Isotoxic High-dose SBRT for Borderline Resectable Pancreatic Adenocarcinoma | Biotech Hunter

Enrollment

256

Participants

Timeline

Start Date

March 24, 2023

Primary Completion Date

December 31, 2027

Study Completion Date

December 31, 2030

Conditions

Pancreatic NeoplasmPancreatic AdenocarcinomaBorderline Resectable Pancreatic Adenocarcinoma

Interventions

DRUG

mFOLFIRINOX or Gemcitabine nab-paclitaxel

oxaliplatin IV, irinotecan IV, leucovorin IV and 5-FU IV OR Gemcitabine IV Nab paclitaxel

RADIATION

Isotoxic High-Dose (iHD)-SBRT

Radiation therapy

PROCEDURE

Surgery

Trial Locations (10)

1070

RECRUITING

Hopital Erasme, HUB, Brussels

RECRUITING

Jules Bordet Institute, HUB, Brussels

1160

RECRUITING

CHIREC, Brussels

1200

RECRUITING

Cliniques Universitaires St luc, Brussels

2650

RECRUITING

Uza Antwerp, Antwerp

4000

RECRUITING

Clinique Chc Montlégia, Liège

7000

RECRUITING

CHU Ambroise Paré, Mons

7100

RECRUITING

Pôle Hospitalier Jolimont, La Louvière

8500

RECRUITING

AZ Groeninge, Kortrijk

9000

NOT_YET_RECRUITING

UZ Gent, Ghent